Karlheinz Schmelig
Directeur/Membre du Conseil chez BIOFRONTERA AG
Profil
Karlheinz Schmelig is currently a Director at CEVEC Pharmaceuticals GmbH, Chundsell Medicals AB, TACALYX GmbH, and a Member-Supervisory Board at Biofrontera AG, Creathor Venture Management GmbH, Phenex Pharmaceuticals AG, Cryotherapeutics SA, and AYOXXA Biosystems GmbH.
He previously served as an Independent Director at Prostatype Genomics AB from 2013 to 2023.
Mr. Schmelig has an undergraduate degree from Duale Hochschule Baden-Württemberg Mannheim and an MBA from Kelley School of Business.
Postes actifs de Karlheinz Schmelig
| Sociétés | Poste | Début |
|---|---|---|
| BIOFRONTERA AG | Directeur/Membre du Conseil | 14/12/2021 |
Creathor Venture Management GmbH
 Creathor Venture Management GmbH Investment ManagersFinance Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions. | Private Equity Investor | 01/01/2004 |
CEVEC Pharmaceuticals GmbH
 CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany. | Directeur/Membre du Conseil | - |
Phenex Pharmaceuticals AG
 Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany. | Directeur/Membre du Conseil | - |
Chundsell Medicals AB
 Chundsell Medicals AB BiotechnologyHealth Technology Chundsell Medicals AB develops and markets novel molecular diagnostics for the treatment of cancer. Its product measures the expression pattern of selected embryonic stem cell genes in prostate cancer core needle biopsies. The company was founded by Sunne Rosell and Chunde Li in 2007 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | - |
AYOXXA Biosystems GmbH
 AYOXXA Biosystems GmbH BiotechnologyHealth Technology AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany. | Directeur/Membre du Conseil | - |
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | - |
Cryotherapeutics SA
 Cryotherapeutics SA Medical SpecialtiesHealth Technology Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany. | Directeur/Membre du Conseil | - |
Anciens postes connus de Karlheinz Schmelig
| Sociétés | Poste | Fin |
|---|---|---|
| PROSTATYPE GENOMICS AB | Directeur/Membre du Conseil | 30/06/2023 |
Formation de Karlheinz Schmelig
| Duale Hochschule Baden-Württemberg Mannheim | Undergraduate Degree |
| Kelley School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PROSTATYPE GENOMICS AB | Health Technology |
| BIOFRONTERA AG | Health Technology |
| Entreprise privées | 7 |
|---|---|
Creathor Venture Management GmbH
Creathor Venture Management GmbH Investment ManagersFinance Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions. | Finance |
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology CEVEC Pharmaceuticals GmbH engages in the manufacture of biopharmaceuticals using a human cell-based expression system. It provides therapeutic proteins and monoclonal antibodies. The company was founded by Stefan Kochanek in 2004 and is headquartered in Cologne, Germany. | Health Technology |
Phenex Pharmaceuticals AG
Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany. | Health Technology |
Chundsell Medicals AB
Chundsell Medicals AB BiotechnologyHealth Technology Chundsell Medicals AB develops and markets novel molecular diagnostics for the treatment of cancer. Its product measures the expression pattern of selected embryonic stem cell genes in prostate cancer core needle biopsies. The company was founded by Sunne Rosell and Chunde Li in 2007 and is headquartered in Solna, Sweden. | Health Technology |
AYOXXA Biosystems GmbH
AYOXXA Biosystems GmbH BiotechnologyHealth Technology AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany. | Health Technology |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Commercial Services |
Cryotherapeutics SA
Cryotherapeutics SA Medical SpecialtiesHealth Technology Cryotherapeutics SA develops and markets a cryotherapy system, with focus on highlighting the safety and efficacy of cryoneergy in the cardiovascular system. The firm specializes in the design of a proprietary system to be used in the treatment of coronary artery diseases that cause heart attacks. Its focus areas encompass technology research, system development, and early-stage product commercialization. The company was founded by Randell L. Werneth, John Yianni and Maurice Buchbinder on September 8, 2009 and is headquartered in Cologne, Germany. | Health Technology |
